HUMAN IMMUNOLOGY, published by Elsevier Science Inc, serves as a critical platform for disseminating research in the fields of immunology and allergy, as well as various aspects of miscellaneous medicine since its inception in 1980. With an ISSN of 0198-8859 and E-ISSN 1879-1166, this journal is pivotal for researchers and practitioners looking to advance their understanding of human immune responses and related conditions. The journal currently holds a respectable position within its field, as highlighted by its 2023 Scopus ranks—#114/233 in Immunology and Allergy and #132/236 in Immunology and Microbiology. Moreover, it maintains a Q2 quartile ranking in both Immunology and Allergy and miscellaneous Medicine, underscoring its influence and reach within the scientific community. Although it does not currently offer Open Access options, HUMAN IMMUNOLOGY remains dedicated to providing valuable insights and fostering academic discourse within its discipline, characterized by a rigorous peer-review process and a focus on innovative research trajectories.

Journal of Immunotoxicology, published by Taylor & Francis Ltd, is at the forefront of research in the intersecting fields of immunology and toxicology. With an annual impact factor that reflects its growing influence, this Open Access journal has been essential for disseminating valuable knowledge since its inception in 2004. The journal welcomes novel research articles, reviews, and commentary that explore the effects of xenobiotics on the immune system, contributing to a deeper understanding of immunotoxicological mechanisms and implications for human health. As a recognized platform, it has achieved commendable rankings in Scopus, positioning it within Q3 in Immunology and Q2 in Toxicology categories as of 2023. This ensures that the journal remains a critical resource for researchers, professionals, and students seeking to advance their knowledge and contribute to the evolving landscape of immunotoxicology. With an Open Access model since 2017, it maximizes accessibility and reaches a global audience, supporting the collaborative efforts needed to address contemporary challenges in health and safety.

ImmunoTargets and Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the field of immunology and its various therapeutic applications. Since its inception in 2012, the journal has rapidly become a vital resource for researchers, professionals, and students, achieving notable recognition with a Q1 ranking in both Immunology and Immunology and Allergy categories as of 2023. With an impressive Scopus ranking of #22 out of 233 in Medicine - Immunology and Allergy, and #25 out of 236 in Immunology and Microbiology, this journal maintains a 90th percentile standing in its field. ImmunoTargets and Therapy not only publishes original research articles, reviews, and clinical studies, but also fosters an inclusive platform for the dissemination of innovative findings critical to the fight against immunological disorders. Based in New Zealand, it serves a global audience, promoting knowledge exchange and collaboration through its open access model.

Journal of Immunology Research, published by HINDAWI LTD, stands as a pivotal open-access journal in the realm of immunology, with a particular emphasis on advancing knowledge in both fundamental and applied aspects of the field. Since its inception in 1990, the journal has committed to the dissemination of high-quality research, earning a respectable impact factor that reflects its significance. Based in Egypt, it provides a platform for researchers from around the world, showcasing innovative studies and reviews that contribute to the understanding of immune system mechanisms. Its 2023 rankings place it in the Q2 category for Immunology and Allergy, and Q1 in the broader category of Medicine (miscellaneous), indicating a strong reputation among its peers. Through its open-access model, the journal promotes wide accessibility of cutting-edge research, catering to researchers, professionals, and students alike. With ambitions that converge through 2024, the Journal of Immunology Research continues to be an essential resource for those seeking to explore the forefront of immunological science.

JOURNAL OF IMMUNOTHERAPY, published by Lippincott Williams & Wilkins, is a premier journal dedicated to advancing the field of immunotherapy, a vital aspect of contemporary cancer research and treatment. With an ISSN of 1524-9557 and an E-ISSN of 1537-4513, this esteemed journal has been disseminating cutting-edge research since 1991 and continues to thrive with a convergence of knowledge leading into 2024. Recognized in the top Q2 quartile for fields such as Cancer Research, Immunology, and Allergy, as well as achieving a Q1 ranking in Pharmacology, the journal serves as a critical resource for researchers, clinicians, and students alike. Its robust impact is reflected in its competitive Scopus rankings across various categories, where it holds significant percentile standings. Highly regarded in the academic community for its rigor, the JOURNAL OF IMMUNOTHERAPY aims to provide a platform for innovative ideas, clinical findings, and experimental research that propels the science of immunotherapy forward. Although it does not offer open access, the journal ensures that its contents remain accessible and impactful for professionals in the field, fostering collaboration and knowledge exchange in an era where immunotherapy holds the promise for breakthroughs in patient care.

Viral Immunology, published by Mary Ann Liebert, Inc, stands as a prominent journal dedicated to advancing the understanding of the interplay between viral infections and host immune responses. With a strong focus on immunology, molecular medicine, and virology, the journal provides a platform for the dissemination of high-quality research findings and innovative methodologies that could shape the future of these critical fields. Although it currently holds a Q3 rating across its relevant categories and a respectable ranking within the Scopus database, Viral Immunology continues to strive for excellence with a commitment to publishing influential research that informs both academic and clinical practices. The journal accepts submissions in various formats—original research, reviews, and commentaries—catering to a diverse readership that includes researchers, professionals, and students engaged in the biological and medical sciences. Readers can anticipate insightful articles that address urgent challenges in immunological responses to viral infections, paving the way for new therapeutic strategies and public health initiatives.

Cancer Immunology Research is a leading journal dedicated to the rapidly evolving field of cancer immunology, published by the American Association for Cancer Research. Established in 2013, this prestigious journal has quickly made a significant impact in its domain, achieving a 2023 Q1 ranking in both Cancer Research and Immunology. With an impressive Scopus rank of 24 out of 230 in cancer research and 28 out of 236 in immunology, it occupies a valuable position for researchers, professionals, and students engaged in cutting-edge cancer studies. Although it does not offer open access, the journal is committed to disseminating high-quality, peer-reviewed research that advances our understanding of the immune system’s role in cancer. The journal's objectives include fostering innovative studies, enhancing collaboration across disciplines, and promoting the translation of research findings into clinical applications, making it a vital resource for anyone invested in cancer therapy and immunological research.

Frontiers in Immunology is a leading open-access journal published by FRONTIERS MEDIA SA since 2010, dedicated to advancing knowledge in the field of immunology. With an impressive Q1 ranking in both Immunology and Allergy as of 2023, this journal exemplifies excellence in research dissemination, positioning itself among the top 22% of relevant literature in the discipline. The journal, based in Switzerland, emphasizes its commitment to open science by ensuring all published research is freely accessible, fostering collaboration and innovation among researchers, professionals, and students alike. With substantial visibility demonstrated by its ranks within the Scopus database—ranked #52 out of 233 in Immunology and Allergy, and #58 out of 236 in Immunology and Microbiology—Frontiers in Immunology serves as a vital platform for cutting-edge research. Researchers are invited to contribute original investigations and reviews that expand the understanding of immune mechanisms, therapeutic advancements, and clinical applications, making it a cornerstone for those looking to push the boundaries of immunological science.

MOLECULAR IMMUNOLOGY, published by Pergamon-Elsevier Science Ltd in the United Kingdom, is a highly regarded journal in the fields of Immunology and Molecular Biology. With a focus on advancing the understanding of the immune system at the molecular level, the journal has been a critical resource since its inception in 1975. The journal is currently listed in the second quartile (Q2) of its category as per the 2023 rankings, indicating its substantial impact in both Immunology and Molecular Biology research. Researchers and professionals benefit from the journal's rigorous peer-review process and its commitment to publishing high-quality original research, reviews, and methodological studies that explore the intricate dynamics of immune responses. Although it does not currently offer an open access option, MOLECULAR IMMUNOLOGY remains an essential platform for scholars, emphasizing the significance of molecular interactions within the immune system and their implications in health and disease.

ACTA PHARMACOLOGICA SINICA is a premier journal in the field of pharmacology, published by the esteemed Nature Publishing Group. With a strong history since its inception in 1980, this journal is recognized for its impactful contributions to the fields of medicine and pharmacology, consistently securing a Q1 ranking in multiple relevant categories, including Pharmacology (Medical). Drawing on a robust international readership, it ranks impressively at #8 out of 272 in the specialty of Medical Pharmacology, placing it in the top 97th percentile according to Scopus data. Although currently not an open-access publication, ACTA PHARMACOLOGICA SINICA remains a vital resource for researchers, professionals, and students seeking to advance their understanding of pharmacological sciences. Its commitment to disseminating high-quality research underscores its significance in fostering innovation and exploration in the medical landscape.